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  Because the intestinal flora is important in the maintaining the 
health of the host, it has gained much attention recently. Glycerol 
monolaurate (GML) is known to inhibit various harmful bacteria 
without inhibiting the growth of lactic acid bacteria (LAB) such as 
Bifidobacterium and Lactobacillus at the 100 ppm level while 
fructooligosaccharides (FOS) are prebiotic food materials which can 
selectively promote the growth of LAB. The objective of this study 
was to observe the effect of combination diets containing GML, FOS, 
and LAB on the composition of the fecal microflora. The 
experimental diets contained GML 1 mg, FOS 5 mg, and LAB (B. 
bifidum BGN4, B. longum BORI, L. acidophilus AD031 at a ratio of 
3:3:4) 4 x 108 CFU each and their combinations per 1 g of feed. 




samples were collected once a week. Total bacteria, 
Bifidobacterium spp., Lactobacillus spp., Bacteroides spp., 
Clostridium butyricum and Enterobacter spp. & Escherichia spp. 
were analyzed with real-time PCR. After 1 week, the number of 
Lactobacillus spp. was significantly increased in the LAB, FOS, GML, 
LAB+FOS and LAB+GML groups (p < 0.01). The number of 
Bifidobacterium spp. was significantly increased in the LAB+FOS 
group (p < 0.05). The numbers of Enterobacter spp. & Escherichia 
spp. were significantly decreased in the FOS and LAB+FOS+GML 
groups. After 2 weeks, the number of Bacteroides spp. was 
significantly reduced in the LAB, FOS, FOS+GML and LAB+FOS 
groups. The GML alone group did not change the number of 
Bacteroides spp. and Enterobacter spp. & Escherichia spp. 
Noticeably, a significant increase in the number of Bifidobacterium 
spp. was observed in mice with a combination of LAB and FOS 
(LAB+FOS), whereas the increase was not significant in the LAB 
alone and FOS alone groups. Taken together, the combination of 
LAB and FOS, but not with GML, could be more effective than LAB 
or FOS alone in improving beneficial intestinal microflora. 
 
Key words: fecal microflora, glycerol monolaurate, 
fructooligosaccharides, lactic acid bacteria, real-time PCR 
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  The intestinal microflora is composed of complex and diverse 
bacteria that play an important role on the maintenance of the 
normal functions in not only intestinal tract but also systemic body 
system. The microflora is related to obesity, diabetes, hypertension 
[1-4], immunity [5, 6], and the absorption of nutrition or drug [7]. 
The beneficial bacteria have a barrier effect that inhibits 
enteropathogenic adhesion to the enterocytes in intestinal tract. 
They also suppress growth of pathogens through competition in the 
use of nutrients by producing antimicrobial metabolite such as 
organic acids and various bacteriocin in intestinal tract [8, 9]. To 
better understand the relation between the intestinal microflora and 
health, analysis of microbial communities is a prerequisite.  
  GML, which is a derivative of lauric acid extracted from coconut 
oil, is formed by the glycerol monoester of lauric acid. GML is 
classified as generally recognized as safe (GRAS) and used in food 
and cosmetics [10, 11]. Food and Drug Administration (FDA) 
regulated GML for use at doses up to 100 mg/ml [12]. GML shows 
antimicrobial properties against virus, Staphylococcus aureus and 
Bacillus anthracis [13-16]. 
  Prebiotics was first defined as a "non-digestible food ingredient 
that beneficially affects the host by selectively stimulating the 
growth and/or activity of one or a limited number of bacteria in the 




available prebiotics such as maltooligosaccharide, 
fructooligosaccharide, galactooligosaccharide, and xylo-
oligosaccharides are widely used in various functional foods. The 
prebiotic effect of these oligosaccharides takes effect through the 
stimulation of the activity and the promotion of growth of the useful 
bacteria such as Bifdobacterium and Lactobacillus [18]. The 
prebiotic effect of FOS have been reported in humans and 
experimental animals [19, 20]. FOS is composed of chains of 
fructose units linked by β(1-2) glycosidic bonds. The number of 
units ranges from 2 to 60 and terminated with a D-glucose unit. 
FOS can be found from plant source such as onions, wheat, garlic, 
bananas, tomatoes, and honey [21]. In addition, there are many 
beneficial effects of FOS on the amelioration of 
glycemia/insulinemia, absorption of mineral, regulation of lipidic 
metabolism, production of short chain fatty acids, relief of the 
constipation, and modulation of the immune systems. Furthermore, 
FOS has low sweetness intensity and play a role as a soluble food 
fibre [22]. 
  Probiotics are defined as "live microorganisms which when 
administered in adequate amounts, confer a health benefit on the 
host” [23] and include commonly Lactobacillus and Bifdobacterium 
[24]. The common features of Lactobacillus and Bifdobacterium are 
gram-positive and nonmotile bacteria. While Lactobacillus grows in 
facultative anaerobic environment, the Bifdobacterium grows in 




are manifested through the suppression of pathogenic bacteria and 
improvement of irritable bowel syndrome, allergy, diarrhea, 
infectious diseases of the intestinal tract, lactose intolerance, and 
constipation [24-31]. They are frequently used in dairy products 
such as yoghurt and cheese, and fermented food such as kimchi and 
pickles. Recently, In order to maintain or modulate the balance of 
intestinal health, the use of supplements using probiotics and 
prebiotics has been increased [24, 32-34].  
  Whereas conventional PCR and fluorescence in situ hybridization 
(FISH) lack the capacity to precisely quantify the target bacteria, 
the recently developed real-time PCR is regarded to present a 
higher sensitivity and rapid quantitative detection for microflora 
assessment from fecal DNA [35-41]. 
  The objective of this research is to observe alteration of fecal 
microbiology in ICR mice fed combination diets containing GML, 
FOS, and LAB. To analyze fecal microflora, this study optimized 
16S rRNA gene-targeted specific primers for Cl. buytiricum, and 
genus primers for the Bifidobacterium spp., Lactobacillus spp., 
Bacteroides spp., Enterobacter spp. & Escherichia spp. and total 








2. Materials and Methods 
 
2.1. Microorganisms  
  The 33 experimental bacterial strains were either obtained from 
the Food Microbiology Laboratory at the Department and Food and 
Nutrition at Seoul National University or purchased from Korean 
Collection for Type Culture. Genomic DNAs from L. rhamnosus 
KCTC 3237, L. acidophilus KCTC 3168, L. casei KFRI 699, L. 
plantarum KFRI 708, L. helveticus ATCC 15009, L. brevis GABA 
100, L. delbrekii KCTC 3188, L. bulgaricus KCTC 3186, L. reuteri 
ATCC 35608, B. longum RD47, B. bifidum BGN4, B. longum BORI, B. 
infantis KCTC 3249, B. breve KCTC 3419, B. adolescentis KCTC 
3216, B. catenulatum KCTC 3221, B. angulatum KCTC 3236, B. 
bifidum KCTC 3418, B. animalis KCTC 3219, Bac. fragils KCTC 
5013, Bac. coprocola KCTC 5443, Bac. cellulosilyticus KCTC 5800, 
Bac. uniformis KCTC 5204, Bac. thetaiotaomicron KCTC 5015, E. 
coli KCTC 1039, Enterococcus faecalis KCTC 3511, Ruminococcus 
gnavus KCTC 5920, Ent. cloacae subsp. cloacae KCTC 2361, 
Prevotella intermedia KCTC 5694, Eubacterium rectale KCTC 5835, 
Cl. butyricum KCTC 1871, Cl. ramosum KCTC 3323, Cl. leptum 
KCTC 5155 were used as positive or negative control strains for 
the validation of real-time PCR conditions for various primers. 
Among the experimental strains, six representative strains were 





2.2. Preparation of diets and animals 
  FOS powder (>95%) and freeze dried strains such as B. bifidum 
BGN4, B. longum BORI, L. acidophilus AD031 were provided by 
Bifido Inc. (Gangwon-do, Korea). GML was purchased from Tokyo 
Chemical Industry CO,.LTD (Tokyo, >97%). The diets were 
prepared containing GML 1 mg, FOS 5 mg, 4 x 108 CFU LAB (B. 
bifidum BGN4, B. longum BORI, L. acidophilus AD031 at a ratio of 
3:3:4) per 1 g of feed (DooYeol Biotech., Seoul, Korea). Five-
week-old male ICR mice strain TAC (n=56, DooYeol Biotech., 
Seoul, Korea) were housed in a room where the temperature was 
kept at 23±3℃ with relative humidity of 50±10% and the light was 
maintained on a 12 h light/dark cycle. All animal studies and 
protocols were approved by Institutional Animal Care and Use 
Committee of Seoul National University. All mice (n=7 per group)  
were accustomed to their new environment for 1 week and 
consumed a commercial diet and tap water ad libitum prior to their 
allocation in one of eight-matched groups. After 1 week, the 
experimental groups consumed a normal diet (AIN-93G) and tap 
water ad libitum for 1 week. After 1 week, mice were fed eight 
different experimental diets for 2 weeks as follows: a normal diet 
group (ND), ND with LAB group (L), ND with FOS group (F), ND 
with GML group (G), ND with FOS+GML group (FG), ND with 
LAB+FOS group (LF), ND with LAB+GML group (LG), ND with 
LAB+FOS+GML group (LFG). Each feces were collected once a 






2.3. DNA extraction from bacterial cell and feces  
  The DNAs from 33 bacterial cells were extracted using MG Cell 
Genomic DNA Extraction SV kit (Doctor protein, Seoul, Korea) in 
triplicate and fecal genomic DNA was extracted using a QIAamp 
DNA minikit (QIAGEN, Hilden, Germany) in septuple. The fecal 
samples were stored at -80℃ until genomic DNA was extracted. 
All DNA samples were eluted in a final volume of 200 μl and 
immediately stored at -20℃until analysis. 
 
2.4. Optimization of real-time PCR conditions for 
primers for fecal microflora analysis 
  The specificity of 11 primer pair was tested in silico by PCR 
simulation using the tools provided in the website 
http://insilico.ehu.es/PCR. The analysis of 11 primers was based on 
real-time PCR using 33 bacteria DNAs. In order to detect target 
bacteria, the optimization of the real-time PCR conditions for the 
primers for Bacteroides spp., Bifidobacterium spp., Lactobacillus 
spp., Prevotella spp., Ruminococcus spp., Enterococcus spp., 
Enterobacter spp. & Escherichia spp., C. coccoides−E. rectale 
group, Cl. butyricum and Cl. leptum subgroup were performed. The 
2% agarose gel was used to measure the amplicon size (data not 
shown). The optimized primers are shown in Table 1 and the real-




Table 1. List of primers used in this study 
Group of species 
or species 



































Table 2. Conditions of real-time PCR for producing standard curve and fecal microflora analysis 














60 30 s 40 30~40 
Lactobacillus spp. 60 1 min 40 17~20 
Bifidobacterium spp. 60 30 s 40 20~22 
Bacteroides spp. 60 30 s 40 30 
Enterobacter spp. 
 & Escherichia spp. 
63 30 s 40 20 




2.5. Standard curves for calculation of the number of 
target bacteria  
  E. coli KCTC 1039 was grown in LB broth and agar (Difco, 
Detroit, MI, USA) under aerobic conditions at 37℃ for 16 h. Ent. 
cloacae subsp. cloacae KCTC 2361 was grown in BHI broth and 
agar (Difco, Detroit, MI, USA) under aerobic conditions at 37℃ for 
18 h. L. acidophilus KCTC 3168 and B. adolescentis KCTC 3216 
were grown in MRS broth and agar (Difco, Detroit, MI, USA) under 
anaerobic conditions at 37℃ for 18 h. Bac. thetaiotaomicron KCTC 
5015 and Cl. butyricum KCTC 1871 were grown in BHI broth and 
agar under anaerobic conditions at 37℃ for 18 h. The viable cell 
number of these bacteria was counted in the respective medium 
agar and genomic DNAs were extracted from the viable cells. Then, 
the extracted DNAs were diluted (10-fold serial dilution) in 
distilled water and then analyzed using real-time PCR in triplicate. 
The real-time PCR conditions are shown Table 2. These results 
were used to make standard curve (Ct=mx+b) for calculation of the 
number of target bacteria. Ct=mx+b described the connection 
between Ct and x (log10 CFU/ml). The m is the slope and b is y-









2.6. Fecal microflora analysis using real-time PCR  
  All fecal DNA samples were examined in duplicate per primer. 
Real-time PCR was performed in a Step one Plus and Step One 
(Applied Biosystems, USA). For the real-time PCR, 20 μl mixture 
per sample was required. The mixture contained DNA 2 μl, 50X 
ROX Reference Dye 0.4 μl, primer pair (10 μM) 0.4 μl, sterile 
distilled water 6.8 μl, and 2X SYBR Premix Ex Taq 10 μl (Takara, 
Japan). The real-time PCR conditions went through an initial 
denaturation step at 95℃ for 30 s followed by 17~40 cycles of at 
95℃ for 5 s and primer annealing at optimal temperature and time 
(Table 2). Real-time PCR results (Ct value) were calculated using 
regression equation of standard curve (Figure 1) and converted to 
the average of target bacteria in 1 g of feces.  
 
2.7. Statistical analysis 
  Data are expressed as mean ± standard error of mean (S.E.M). 
The results obtained from 3 weeks were compared using a 
nonparametric one way ANOVA test (Kruskal-Wallis H) and 
Mann-Whitney U test. Differences of p < 0.05 or p < 0.01 were 
considered statistically significant. All data analysis was performed 







Figure 1. Standard curve for calculation of the number of target bacteria 
 (A) Total bacteria (Universal) (B) Bifidobacterium spp. (C) Lactobacillus spp. (D) 









































































































log 10 CFU/ml 
Enterobacter spp. & 


























3. Results  
 
3.1. Optimization of real-time PCR conditions for 
primers 
  Validation of the real-time PCR conditions for primers was 
successful for 6 of the 11 primers. These validated primers 
included total bacteria, Lactobacillus spp., Bifidobacterium spp., 
Bacteroides spp., Enterobacter spp. & Escherichia spp. and Cl. 
butyricum. 
 
3.2. Alteration of fecal microflora in ICR mice  
  Until the end of the experiment, the number of total bacteria was 
about 1010 CFU/g for all the experimental groups (Table 3 and 
Figure 2), and Cl. butyricum was not detected in any group of the 
ICR mice strain TAC. The ND group, which was fed a normal diet, 
showed the lowest number of Bifidobacterium spp. and Lactobacillus 
spp. and the highest number of Bacteroides spp. and Enterobacter 










Table 3. Changes of total bacteria in feces during the experiment 




0 week 1 week 2 week 
Ct value 10
10 
CFU/g Ct value 10
10
 CFU/g Ct value 10
10 
CFU/g 
ND 8.66  5.32±0.71 8.82  4.92±1.01  9.73  2.06±0.27 
L 8.09  9.26±1.74 8.16  8.15±1.12 8.16  8.39±1.32 
F 8.96  4.83±1.20  8.86  4.49±0.68 8.80  9.09±2.95 
G 9.53  2.36±0.12 8.85  4.78±0.96  10.36  1.45±0.32 
FG 9.17  4.92±1.95 8.81  5.49±1.64 9.33  2.97±0.41 
LF 9.55  2.39±0.28 8.66  6.33±1.68 9.70  2.04±0.13 
LG 8.95  4.59±1.08 8.62  5.53±0.77 9.89  1.83±0.28 
LFG 9.47  2.54±0.24 8.70  5.15±0.65 * 8.91  4.78±1.12 
  0 week is a day which the diets of the mice were switched from the normal diet to the corresponding experimental diets. Changes in absolute 
number in total bacteria for a normal diet group (ND), ND with LAB (L), ND with FOS (F), ND with GML (G), ND with FOS+GML (FG), ND 
with LAB+FOS (LF), ND with LAB+GML (LG), ND with LAB+FOS+GML (LFG).  
Bacterial count expressed as mean ± S.E.M. x 10
10 
CFU per gram of feces. Ct value expressed as mean. 





Figure 2. Changes of total bacteria in feces during the experiment 
  0 week is a day which the diets of the mice were switched from the normal diet 
to the corresponding experimental diets. Changes in absolute number in total 
bacteria for a normal diet group (ND), ND with LAB (L), ND with FOS (F), ND 
with GML (G), ND with FOS+GML (FG), ND with LAB+FOS (LF), ND with 
LAB+GML (LG), ND with LAB+FOS+GML (LFG). The results are shown as 
means and error bar is S.E.M. of target bacteria in 1 g of feces.  
10
n
 expressed E+number.  









































3.2.1. Alteration of the number of Lactobacillus spp. 
  After 1 week, the number of Lactobacillus spp. varied from 6.64 x 
107 to 1.51 x 109 CFU/g in the experimental groups. The levels of 
the L, F, G, LF and LG groups were significantly increased (p < 
0.01) except for the ND, FG and LFG groups (Table 4 and Figure 
3). The levels of these five groups increased 26, 5.53, 4.37, 14.61 
and 8.54 fold, respectively.  
  After 2 weeks compared to 0 week, the number of Lactobacillus 
spp. ranged from 6.51 x 107 to 3.77 x 109 CFU/g in all the 
experimental groups (Table 4 and Figure 3). Although the number 
of Lactobacillus spp. was increased in the L, F, G, LF and LG groups, 













Table 4. Changes of Lactobacillus spp. in feces during the experiment 




0 week 1 week 2 week 
Ct value 10
8
 CFU/g Ct value 10
8
 CFU/g Ct value 10
8
 CFU/g 
ND 14.94  0.62±0.14 14.97  0.66±0.19 14.78  0.65±0.11 
L 13.47  1.59±0.24
 
10.64  13.14±3.99 ** 12.50  3.37±0.77 
F 14.52  0.89±0.27 11.87  4.90±0.78 ** 13.32  1.68±0.17 
G 13.75  1.30±0.21 11.60  5.70±0.96 ** 13.31  2.14±0.57 
FG 12.02  4.34±0.78 11.75  9.21±3.32 12.54  3.04±0.48 
LF 14.09  1.04±0.17 10.51  15.1±5.26 ** 13.22  1.92±0.31 
LG 14.25  0.93±0.15 11.11  7.93±1.10 ** 13.04  2.64±0.73 
LFG 12.09  4.44±0.87 11.32  6.82±0.86 12.83  3.77±2.08 
  0 week is a day which the diets of the mice were switched from the normal diet to the corresponding experimental diets. Changes in absolute 
number in Lactobacillus spp. for a normal diet group (ND), ND with LAB (L), ND with FOS (F), ND with GML (G), ND with FOS+GML (FG), ND 
with LAB+FOS (LF), ND with LAB+GML (LG), ND with LAB+FOS+GML (LFG). 
Bacterial count expressed as mean ± S.E.M. x 10
8 
CFU per gram of feces. Ct value expressed as mean. 






Figure 3. Changes of Lactobacillus spp. in feces during the experiment 
  0 week is a day which the diets of the mice were switched from the normal diet 
to the corresponding experimental diets. Changes in absolute number in 
Lactobacillus spp. for a normal diet group (ND), ND with LAB (L), ND with FOS 
(F), ND with GML (G), ND with FOS+GML (FG), ND with LAB+FOS (LF), ND 
with LAB+GML (LG), ND with LAB+FOS+GML (LFG). The results are shown as 















































3.2.2. Alteration of the number of Bifidobacterium spp. 
  After 1 week, the number of Bifidobacterium spp. varied from 
1.86 x 108 to 1.74 x 109 CFU/g in all the experimental groups 
(Table 5 and Figure 4). Only the number of Bifidobacterium spp. 
was significantly increased in the LF group (p < 0.05).  
  After 2 weeks compared to 0 week, the number of 
Bifidobacterium spp. ranged from 2.21 x 108 to 1.64 x 109 CFU/g in 
the experimental groups (Table 5 and Figure 4). The number of 
Bifidobacterium spp. was increased in all the experimental groups. 




Table 5. Changes of Bifidobacterium spp. in feces during the experiment 




0 week 1 week 2 week 
Ct value 10
8 
CFU/g Ct value 10
8 
CFU/g Ct value 10
8 
CFU/g 
ND 16.53  1.62±1.19 17.25  1.86
 
±0.85 16.90  2.21±0.84 
L 14.51  7.39±2.83 13.70  17.37±4.73 14.54  10.89±3.89 
F 15.48  3.57±1.53 15.31  4.48±0.70 14.85  8.30±3.13 
G 14.87  5.68±1.85 15.67  5.02±2.05 15.40  6.95±2.39 
FG 16.69  1.44±0.75 16.75  6.53±2.18 15.39  5.16±1.51 
LF 15.39  3.83±0.50 14.13  13.00±3.92 * 14.53  13.60±6.31 
LG 15.34  3.97±2.02 13.75  16.47±5.22 15.42  8.51±4.49 
LFG 14.34  8.42±3.06 14.09  14.24±5.59 14.26  16.42±7.22 
  0 week is a day which the diets of the mice were switched from the normal diet to the corresponding experimental diets. Changes in absolute 
number in Bifidobacterium spp. for a normal diet group (ND), ND with LAB (L), ND with FOS (F), ND with GML (G), ND with FOS+GML (FG), 
ND with LAB+FOS (LF), ND with LAB+GML (LG), ND with LAB+FOS+GML (LFG).  
Bacterial count expressed as mean ± S.E.M. x 10
8 
CFU per gram of feces. Ct value expressed as mean. 





Figure 4. Changes of Bifidobacterium spp. in feces during the experiment 
  0 week is a day which the diets of the mice were switched from the normal diet 
to the corresponding experimental diets. Changes in absolute number in 
Bifidobacterium spp. for a normal diet group (ND), ND with LAB (L), ND with FOS 
(F), ND with GML (G), ND with FOS+GML (FG), ND with LAB+FOS (LF), ND 
with LAB+GML (LG), ND with LAB+FOS+GML (LFG). The results are shown as 














































3.2.3. Alteration of the number of Bacteroides spp. 
  After 1 week, the number of Bacteroides spp. varied from 6.92 x 
108 to 3.50 x 109 CFU/g in the experimental groups (Table 6 and 
Figure 5), while their levels were not significantly changed. 
  After 2 weeks compared to 0 week, the number of Bacteroides 
spp. ranged from 3.24 x 108 to 1.59 x 109 CFU/g in the experimental 
groups (Table 6 and Figure 5). The levels of the L and FG groups 
were significantly decreased (p < 0.01). Second, the levels of the F 
and LF groups were significantly reduced (p < 0.05). A reduction of 
45% or more of Bacteroides spp. was seen in the L (61%), F (49%), 


























Table 6. Changes of Bacteroides spp. in feces during the experiment 




0 week 1 week 2 week 
Ct value 10
8 
CFU/g Ct value 10
8 
CFU/g Ct value 10
8 
CFU/g 
ND 11.46  25.38±4.90 11.04  35.02
 
±5.65 11.99  15.95±2.61 
L 12.74  8.37±1.31 12.93  7.56±1.51 13.97  3.24±0.05 ** 
F 12.57  9.32±1.17 12.87  8.20±1.64 13.39  4.80±0.07 * 
G 12.67  8.75±1.30 12.67  8.20±2.25 13.23  5.72±1.17 
FG 12.42  10.78±1.48 13.02  6.92±1.33 13.76  3.52±0.06 ** 
LF 12.35  11.23±1.42 12.65  9.87±2.85 13.35  5.14±0.09 * 
LG 12.13  15.53±4.15 12.34  11.63±1.79 12.43  11.50±2.33 
LFG 12.10  14.55±2.45 12.94  8.75±3.23 12.95  7.26±1.33 
  0 week is a day which the diets of the mice were switched from the normal diet to the corresponding experimental diets. Changes in absolute 
number in Bacteroides spp. for a normal diet group (ND), ND with LAB (L), ND with FOS (F), ND with GML (G), ND with FOS+GML (FG), ND 
with LAB+FOS (LF), ND with LAB+GML (LG), ND with LAB+FOS+GML (LFG). 
Bacterial count expressed as mean ± S.E.M. x 10
8 
CFU per gram of feces. Ct value expressed as mean. 





Figure 5. Changes of Bacteroides spp. in feces during the experiment 
  0 week is a day which the diets of the mice were switched from the normal diet 
to the corresponding experimental diets. Changes in absolute number in 
Bacteroides spp. for a normal diet group (ND), ND with LAB (L), ND with FOS (F), 
ND with GML (G), ND with FOS+GML (FG), ND with LAB+FOS (LF), ND with 
LAB+GML (LG), ND with LAB+FOS+GML (LFG). The results are shown as 














































3.2.4. Alteration of the number of Enterobacter spp. & 
Escherichia spp. 
  After 1 week, the number of Enterobacter spp. & Escherichia spp. 
varied from 1.82 x 108 to 3.64 x 109 CFU/g in the experimental 
groups (Table 7 and Figure 6). The levels of Enterobacter spp. & 
Escherichia spp. in the F and LFG groups were significantly reduced 
(p < 0.01 and p < 0.05, respectively). A more than 70% reduction of 
Enterobacter spp. & Escherichia spp. was observed in the F (70%) 
and LFG (75%) groups. 
  After 2 weeks compared to 0 week, the number of Enterobacter 
spp. & Escherichia spp. ranged from 2.40 x 108 to 4.43 x 109 CFU/g 
in all the experimental groups (Table 7 and Figure 6). A significant 







Table 7. Changes of Enterobacter spp. & Escherichia spp. in feces during the experiment 




0 week 1 week 2 week 
Ct value 10
8 
CFU/g Ct value 10
8 
CFU/g Ct value 10
8 
CFU/g 
ND 15.69  10.43±6.41 15.48  36.36±31.84 14.54  44.25±27.72 
L 14.78  22.09±9.95 15.11  8.11±7.48 15.72  4.88±2.23 
F 14.83  10.76±1.32 16.22  3.23±1.25 ** 15.88  4.26±2.28 
G 16.46  2.73±0.29 16.01  3.84±1.50 16.14  3.46±1.77 
FG 15.64  6.08±1.36 15.79  7.73±3.61 16.78  2.40±0.05 
LF 14.77  15.54±5.49 15.34  6.68±3.17 15.00  8.88±2.47 
LG 15.14  7.93±4.15 15.78  7.57±3.03 15.27  7.13±2.18 
LFG 15.36  7.29±1.30 16.91  1.82±0.10 * 16.76  2.76±1.09 
  0 week is a day which the diets of the mice were switched from the normal diet to the corresponding experimental diets. Changes in absolute 
number in Enterobacter spp. & Escherichia spp. for a normal diet group (ND), ND with LAB (L), ND with FOS (F), ND with GML (G), ND with 
FOS+GML (FG), ND with LAB+FOS (LF), ND with LAB+GML (LG), ND with LAB+FOS+GML (LFG). Bacterial count expressed as mean ± 
S.E.M. x 10
8 
CFU per gram of feces. Ct value expressed as mean. 






Figure 6. Changes of Enterobacter spp. & Escherichia spp. in feces during 
the experiment 
  0 week is a day which the diets of the mice were switched from the normal diet 
to the corresponding experimental diets. Changes in absolute number in 
Enterobacter spp. & Escherichia spp. for a normal diet group (ND), ND with LAB 
(L), ND with FOS (F), ND with GML (G), ND with FOS+GML (FG), ND with 
LAB+FOS (LF), ND with LAB+GML (LG), ND with LAB+FOS+GML (LFG). The 
results are shown as means and error bar is S.E.M. of target bacteria in 1 g of 
feces. 10
n
 expressed E+number.  





































  Originally, our aim was to detect the ten genera inhabiting the 
intestinal system. However, validation of the real-time PCR 
conditions for genus specific primers for Prevotella spp., 
Ruminococcus spp., Enterococcus spp., C. coccoides−E. rectale 
group, and Cl. leptum subgroup. was not successful due to non-
specific amplification and other various reasons (data not shown). 
In this study, amplification with optimized real-time PCR conditions 
was performed to quantify total bacteria, Lactobacillus spp., 
Bifidobacterium spp., Bacteroides spp., Enterobacter spp. & 
Escherichia spp. and Cl. butyricum.  
  Even though real-time PCR for Cl. butyricum worked well, it was 
not found in any of the experimental groups. Because the murine 
intestinal tract is inhabited by complex and diverse microbial 
communities, the analysis of microflora is complex and difficult to 
interpret. Other studies have suggested that the composition of the 
microflora is different between this mouse strain and other 
vertebrates [35, 45, 46]. Additionally, there are genetic and life 
cycle as well as individual and environmental effects on the 
microflora [47-53]. The influence of these factors could have 
contributed to the inconsistent patterns in the number of 
Lactobacillus spp. and Enterobacter spp. & Escherichia spp. during 
the experiment (Tables 4 and 7).  
  Kabara and coworker [54] investigated fatty acids with high 




acid against microorganisms is carbon C12 with monoglycerides. 
GML is a lauric acid (C12) esterified with glycerol. The distortion 
of the bacterial membrane lipid by GML may hinder the absorption 
of the nutrients, and thus suppress the growth of bacteria [55]. 
Despite the expected antimicrobial effects, GML had no effect on 
the composition of Bacteroides spp. and Enterobacter spp. & 
Escherichia spp. in this study. The relative resistance of the gram-
negative bacteria to the GML because of the presence of cell wall 
lipopolysaccharides [56] and the reduction in the effective level of 
GML in the gut due to the interaction of GML with the intestinal lipid 
components and digestive absorption might have contributed to the 
presently observed ineffectiveness of GML [57].  
  Because FOS, which is a non-digestible oligosaccharide, can pass 
through the upper gut and reach the intestinal tract, this is 
selectively fermented by colonic bacteria and modulates the gut 
microflora affecting the host health [58, 59]. Previous studies used 
a mixture of GOS/FOS at a ratio of 9:1 and showed their health-
promoting effects. [60-62]. This study used only FOS to just 
observe the prebiotic effect alone [63, 64]. The growth of 
Bifidobacterium was stimulated after the consumption of prebiotics 
at least 2 weeks [61]. The present study showed an increase in 
fecal bifidobacteria in the F, FG, LF and LFG groups when fed FOS. 
However, a significant increase in the number of Bifidobacterium 
spp. was observed only in the LF group.  




Lactobacillus spp. was observed in the L and LG groups. The 
numbers of Bifidobacterium spp. and Lactobacillus spp. were 
significant in the LF group after 1 week. In this study, multispecies 
probiotics were used for the beneficial improvement of the fecal 
microflora including two Bifidobacterium species and one 
Lactobacillus species. Lactobacillus acidophilus among the LAB is 
well known as a probiotics. [24, 65]. In a previous study, B. bifidum 
BGN4 revealed a noticeable adhesive capability for intestinal 
epithelial cells. The properties of B. bifidum BGN4 are suitable for a 
probiotic effect and is effective against inflammatory bowel disease 
[66]. B. longum BORI has an clinical effect in rotavirus-infected 
children [67]. Other studies have reported that multistrain were 
more effective than a single strain in alleviating irritable bowel 
syndrome symptom and antibiotic-associated diarrhea in children 
as well as more effective against pathogenic bacteria [65].  
  In the present study, the effects of combining three substances 
were as follows. A significant decrease in the number of 
Bacteroides spp. was observed in the L, F, FG and LF groups. The 
number of Enterobacter spp. & Escherichia spp. was significantly 
reduced in the F and LFG groups. A significant increase in the 
number of Lactobacillus spp. was observed in the L, F, G, LF and 
LG groups (p < 0.01). Meanwhile, the numbers of these bacteria did 
not have any significant differences between the combination diets 
and non-combination diets, whereas the number of Bifidobacterium 




  These results show that the combination of LAB and FOS is more 
effective in the promotion of Bifidobacterium spp. than LAB alone or 
FOS alone.  
 
5. Conclusion  
  Taken together, the present study showed that the intake of three 
substances (GML, FOS and LAB) altered the fecal microflora 
differently. The effect of the combined LAB and FOS could be more 
effective than LAB or FOS alone in improving beneficial intestinal 
microflora. Because quantification analysis of fecal microflora in ICR 
mice fed combinations of different food materials (GML, FOS, and 
specific multistrain probiotics) is less well studied, this research 
contributes to providing knowledge on the effect of various 
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Abstract in Korean 
  장내 미생물은 숙주의 건강을 유지하는데 중요하기 때문에 관련 
연구가 증가하고 있다. 글리세롤 모노라우레이트 (GML)는 다양한 
유해균을 저해하는 것으로 알려져 있다. 프락토올리고당 (FOS)은 
프리바이오틱 효과가 있어 Bifidobacterium과 Lactobacillus와 같은 
유산균의 성장을 촉진 시킬 수 있다. 유산균 (LAB)은 프로바이오틱 
효과가 있어 위 3가지 물질은 장내 미생물에 영향을 미칠 수 있다.  
  연구 목적은 글리세롤 모노라우레이트, 프락토올리고당 및 유산균을 
사료에 첨가하여 3가지 물질의 조합식이 섭취가 분변미생물에 미치는 
영향을 관찰하는 것이다. 
  사료 1 g에 GML 1 mg, FOS 5 mg, 4 x 108 CFU LAB (3:3:4 비율의 
B. bifidum BGN4, B. longum BORI, L. acidophilus AD031)를 각 군에 
해당하는 물질을 첨가하여 제조하였다. 총 56마리의 ICR 쥐에게 2주 
동안 각 군에 해당하는 실험식이를 섭취시켰고 분변은 일주일에 한 번씩 
수집하였다. Real-time PCR의 조건을 최적화한 primer인 Total 
bacteria, Bifidobacterium spp., Lactobacillus spp., Bacteroides spp., 
Clostridium butyricum, Enterobacter spp. & Escherichia spp.에 
대하여 분변미생물을 정량분석 하였다. 
  식이 섭취 1주일 후, Lactobacillus spp.는 LAB, FOS, GML, 
LAB+FOS 및 LAB+GML을 섭취한 군에서 유의적으로 증가했고 (p < 
0.01) Bifidobacterium spp.은 LAB+FOS를 섭취한 군에서 유의적으로 
증가했다 (p < 0.05). Enterobacter spp. & Escherichia spp.는 FOS 및 




2주일 후, Bacteroides spp.는 LAB, FOS, FOS+GML 및 LAB+FOS 
성분이 포함된 군에서 유의적으로 감소했다. 단일 GML에서 
Bacteroides spp.와 Enterobacter spp. & Escherichia spp.의 수는 
변하지 않았다. 본 연구는 LAB와 FOS가 조합된 군에서 
Bifdobacterium의 수가 유의적으로 증가한 반면 단일 LAB와 단일 
FOS에서는 증가하지 않았다. GML을 제외하고 LAB와 FOS의 조합은 
장내 균총 개선에 단일 FOS 또는 단일 LAB보다 더 효과적일 것이다.  
 
주요어: 분변 균총, 글리세롤 모노라우레이트, 프락토올리고당, 유산균, 
real-time PCR 
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